Across TCGA pan-cancer cohorts, ZCCHC13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZCCHC13 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZCCHC13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZCCHC13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, LUAD, and UCEC are the cancer types where ZCCHC13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.146	0.579	<.001	30	view →
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZCCHC13 tumor-vs-normal RNA expression · all ZCCHC13 data types